Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Sponsor: ADARx Pharmaceuticals, Inc.
Summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Official title: A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2025-11-10
Completion Date
2027-12
Last Updated
2026-03-02
Healthy Volunteers
No
Interventions
ADX-038
siRNA duplex oligonucleotide
Placebo
Saline
Locations (17)
ADARx Clinical Site
Gilbert, Arizona, United States
ADARx Clinical Site
Phoenix, Arizona, United States
ADARx Clinical Site
Beverly Hills, California, United States
ADARx Clinical Site
Huntington Beach, California, United States
ADARx Clinical Site
Poway, California, United States
ADARx Clinical Site
Orlando, Florida, United States
ADARx Clinical Site
Hagerstown, Maryland, United States
ADARx Clinical Site
Erie, Pennsylvania, United States
ADARx Clinical Site
McAllen, Texas, United States
ADARx Clinical Site
Round Rock, Texas, United States
ADARx Clinical Site
San Antonio, Texas, United States
ADARx Clinical Site
The Woodlands, Texas, United States
ADARx Clinical Site
Albury, New South Wales, Australia
ADARx Clinical Site
Parramatta, New South Wales, Australia
ADARx Clinical Site
Rowville, Victoria, Australia
ADARx Clinical Site
Ottawa, Ontario, Canada
ADARx Clinical Site
Toronto, Ontario, Canada